Biocon and Mylan NV have launched Ogivri (trastuzumab-dkst), a biosimilar to Herceptin (trastuzumab) in US. Ogivri is available in a 420 mg multi-dose vial and a 150 mg single-dose vial in order to provide patient dosing and treatment flexibility.
Ogivri was the first biosimilar trastuzumab approved by the US Food and Drug Administration (USFDA) and unanimously recommended by the USFDA Oncologic Drugs Advisory Committee (ODAC).
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
